Clinical Trial Update: Early Surfactant Administration at FiO₂ >0.25 Under NIPPV for RDS in Very Preterm Infants [NA]

View source ↗

Summary

Clinical trial entry evaluating early surfactant administration at FiO2 > 0.25 under NIPPV for respiratory distress syndrome in very preterm infants; recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Snippet

Sponsor: Jiulongpo No.1 People's Hospital | Conditions: Respiratory Distress Syndrome (&Amp; [Hyaline Membrane Disease]) | NA | Status: NOT_YET_RECRUITING